MX338513B - Acidos grasos de longitud de cadena mediana y gliceridos como agentes de nefroprotección. - Google Patents

Acidos grasos de longitud de cadena mediana y gliceridos como agentes de nefroprotección.

Info

Publication number
MX338513B
MX338513B MX2010004856A MX2010004856A MX338513B MX 338513 B MX338513 B MX 338513B MX 2010004856 A MX2010004856 A MX 2010004856A MX 2010004856 A MX2010004856 A MX 2010004856A MX 338513 B MX338513 B MX 338513B
Authority
MX
Mexico
Prior art keywords
nephroprotection
agents
medium
fatty acids
chain length
Prior art date
Application number
MX2010004856A
Other languages
English (en)
Other versions
MX2010004856A (es
Inventor
Lyne Gagnon
Vincent Pichette
Francois Leblond
Mouna Lagraoui
Original Assignee
Prometic Pharma Smt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Pharma Smt Ltd filed Critical Prometic Pharma Smt Ltd
Publication of MX2010004856A publication Critical patent/MX2010004856A/es
Publication of MX338513B publication Critical patent/MX338513B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe el uso de ácidos grasos de longitud de cadena mediana tales como ácido cáprico, ácido caprílico o ácido láurico y sus sales o mono- o di- o triglicéridos como agentes de nefroprotección para protegerlos contra la progresión de insuficiencia renal en enfermedades crónicas del riñón. Esto incluye el tratamiento de enfermedades del riñón asociadas con nefrectomía, fibrosis renal, esclerosis glomerular y enfermedad renal de etapa terminal. También incluye la protección del riñón contra el agente citotóxico usado en la quimioterapia o enfermedades autoinmunes o trasplante. Además incluye el tratamiento de la progresión de la insuficiencia renal asociada con la hipertensión, infarto, tumor, diabetes mellitus, autoinmunidad o inflamación.
MX2010004856A 2007-11-02 2008-11-03 Acidos grasos de longitud de cadena mediana y gliceridos como agentes de nefroprotección. MX338513B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98509407P 2007-11-02 2007-11-02
PCT/CA2008/001930 WO2009055933A1 (en) 2007-11-02 2008-11-03 Medium-chain length fatty acids and glycerides as nephroprotection agents

Publications (2)

Publication Number Publication Date
MX2010004856A MX2010004856A (es) 2010-06-30
MX338513B true MX338513B (es) 2016-04-20

Family

ID=40590499

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004856A MX338513B (es) 2007-11-02 2008-11-03 Acidos grasos de longitud de cadena mediana y gliceridos como agentes de nefroprotección.

Country Status (19)

Country Link
US (1) US9532962B2 (es)
EP (1) EP2299998B1 (es)
JP (1) JP5575655B2 (es)
KR (1) KR101601987B1 (es)
CN (1) CN101878028A (es)
AU (1) AU2008318196B2 (es)
BR (1) BRPI0818310A8 (es)
CA (1) CA2704286C (es)
DK (1) DK2299998T3 (es)
ES (1) ES2664594T3 (es)
IL (1) IL205362A (es)
MX (1) MX338513B (es)
MY (1) MY151439A (es)
NO (1) NO2299998T3 (es)
NZ (1) NZ584981A (es)
PT (1) PT2299998T (es)
RU (1) RU2519215C2 (es)
WO (1) WO2009055933A1 (es)
ZA (1) ZA201003030B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2427416E (pt) 2009-05-04 2016-06-15 Prometic Pharma Smt Ltd Compostos aromáticos substituídos e seus usos farmacêuticos
JP5706142B2 (ja) * 2010-04-28 2015-04-22 株式会社ファンケル フユボダイジュ花のエタノール抽出物を有効成分とする血中グルコース低下剤、内臓脂肪蓄積抑制剤、ｔｇ低下剤、糞中脂肪排泄促進剤
EA035494B1 (ru) * 2010-10-27 2020-06-25 Прометик Фарма Смт Лимитед Способ и применение композиции для ингибирования миграции клеток опухоли и образования метастазов
WO2013031729A1 (ja) 2011-08-26 2013-03-07 国立大学法人大阪大学 糖尿病性心血管合併症の予防・治療剤
KR20130023583A (ko) * 2011-08-29 2013-03-08 아주대학교산학협력단 파골세포 형성 억제 효과가 있는 카프르산 및 이를 포함하는 약학적 조성물
US10130603B2 (en) 2013-11-05 2018-11-20 Colgate-Palmolive Company Methods and compositions for improving kidney function
WO2017074266A1 (en) * 2015-10-30 2017-05-04 National University Of Singapore Androgen biosynthesis inhibitor
CN105559071A (zh) * 2016-01-12 2016-05-11 刘保惠 一种适用于肾病的特殊医学用途配方食品及其制备方法
JP2017214342A (ja) * 2016-06-02 2017-12-07 日清オイリオグループ株式会社 排尿障害の予防用又は改善用組成物
CN110300581B (zh) 2016-06-08 2023-09-08 善睿圣医药保健股份有限公司 具有奇数碳的脂类化合物及其作为医药组合物或者营养补充剂的用途
WO2018115953A1 (en) * 2016-12-21 2018-06-28 Prometic Pharma Smt Limited Methods and compositions for preventing or minimizing epithelial-mesenchymal transition
WO2019082912A1 (ja) * 2017-10-27 2019-05-02 学校法人北里研究所 慢性腎臓病の予防又は治療剤
WO2019155336A1 (en) * 2018-02-08 2019-08-15 Societe Des Produits Nestle S.A. Mct-based nutrition blend for providing health benefits in companion animals
SG11202103011YA (en) 2018-10-11 2021-04-29 Basf As Aromatic compounds and pharmaceutical uses thereof
CN109602012A (zh) * 2018-12-11 2019-04-12 李卫平 一种功能性低蛋白能量米及其制备方法
CN111184728B (zh) * 2020-02-20 2023-04-04 上海市儿童医院 海藻糖在肾病综合征中的应用
AU2023292465A1 (en) * 2022-06-15 2024-12-12 Hill's Pet Nutrition, Inc. Pet food compositions
CN118592613B (zh) * 2024-08-05 2025-01-07 杭州康源食品科技有限公司 中链脂肪酸混合结构脂在改善膳食诱导的糖脂代谢紊乱中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602040A (en) 1983-04-18 1986-07-22 Warner-Lambert Company Meclofenamic acid topical pharmaceutical composition
US4737384A (en) * 1985-11-01 1988-04-12 Allied Corporation Deposition of thin films using supercritical fluids
CA2107581A1 (en) * 1992-02-07 1993-08-08 Kiyoshi Sugiyama Side-effect alleviant
US6689700B1 (en) * 1999-11-02 2004-02-10 University Of Massachusetts Chemical fluid deposition method for the formation of metal and metal alloy films on patterned and unpatterned substrates
CN100348183C (zh) 2000-06-20 2007-11-14 营养科学公司 可用作抗微生物剂的中链脂肪酸
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
BR0208984A (pt) * 2001-04-18 2004-06-29 Prometic Biosciences Inc ácidos graxos, glicerìdeos e análogos de comprimento de cadeia médio como fatores de sobrevivência e ativação de neutrófilos
CN1827766B (zh) * 2001-06-28 2010-08-25 徐荣祥 体外细胞的培养方法
RU2213570C2 (ru) * 2001-08-22 2003-10-10 Санкт-Петербургская Государственная Химико-Фармацевтическая Академия ЛЕЧЕБНО-ПРОФИЛАКТИЧЕСКОЕ СРЕДСТВО ИЗ ЛИСТЬЕВ ЛИПЫ Folia Tilia И СПОСОБ ПОЛУЧЕНИЯ ЭКСТРАКТИВНЫХ ВЕЩЕСТВ
US7030168B2 (en) * 2001-12-31 2006-04-18 Advanced Technology Materials, Inc. Supercritical fluid-assisted deposition of materials on semiconductor substrates
US20040052836A1 (en) * 2002-09-13 2004-03-18 Li Luk Chiu Pharmaceutical compositions containing at least one stable liposphere having an improved shelf life
US9682054B2 (en) * 2003-02-07 2017-06-20 Prometic Pharma Smt Limited Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis
AU2004261461B2 (en) * 2003-07-25 2008-12-18 Prometic Pharma Smt Limited Preparation of metal salts of medium-chain fatty acids
EP1940379A4 (en) * 2005-09-30 2009-05-13 Jackson H M Found Military Med METHOD FOR THE TREATMENT OF HEMORRHAGIC SHOCKS AND ASSOCIATED DISEASES

Also Published As

Publication number Publication date
EP2299998B1 (en) 2018-01-03
IL205362A0 (en) 2010-12-30
KR20100106958A (ko) 2010-10-04
PT2299998T (pt) 2018-04-02
EP2299998A4 (en) 2011-03-30
RU2010122302A (ru) 2011-12-10
NO2299998T3 (es) 2018-06-02
ES2664594T3 (es) 2018-04-20
CN101878028A (zh) 2010-11-03
US9532962B2 (en) 2017-01-03
WO2009055933A1 (en) 2009-05-07
US20100286269A1 (en) 2010-11-11
CA2704286A1 (en) 2009-05-07
DK2299998T3 (en) 2018-03-26
EP2299998A1 (en) 2011-03-30
IL205362A (en) 2015-01-29
KR101601987B1 (ko) 2016-03-09
RU2519215C2 (ru) 2014-06-10
AU2008318196B2 (en) 2014-04-10
ZA201003030B (en) 2011-02-23
MX2010004856A (es) 2010-06-30
CA2704286C (en) 2016-08-23
AU2008318196A1 (en) 2009-05-07
JP2011502174A (ja) 2011-01-20
MY151439A (en) 2014-05-30
BRPI0818310A8 (pt) 2017-12-26
NZ584981A (en) 2012-05-25
JP5575655B2 (ja) 2014-08-20
BRPI0818310A2 (pt) 2017-10-10

Similar Documents

Publication Publication Date Title
MX338513B (es) Acidos grasos de longitud de cadena mediana y gliceridos como agentes de nefroprotección.
WO2007073486A3 (en) Methods and compositions for delivering active agents with enhanced pharmacological properties
NZ591057A (en) Complement antagonists and uses thereof
EP2671584A3 (en) Compositions and methods for treating disorders associated with salt or fluid retention
CL2012002317A1 (es) Compuestos derivados de tienopirimidinas, inhibitores de quinasas mnk1/mnk2; composicion farmaceutica; y su uso para elt ratamiento o profilaxis de enfermedades metabolicas, tales como diabetes, daño renal, cancer, enfermedades inflamatorias, entre otras.
WO2009109927A3 (en) Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
WO2012019188A3 (en) Methods and compositions for the inhibition of fructokinase
EP4678242A3 (en) Pharmaceutical composition, methods for treating and uses thereof
NZ700881A (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
TR201901110T4 (tr) Empagliflozinin terapötik kullanımları.
EP2638903A4 (en) SUPPRESSOR FOR INCREASING THE BLOOD SUGAR MIRROR
EA200901155A1 (ru) Модуляторы фармакокинетических свойств терапевтических препаратов (варианты) и их использование в терапии
MX381737B (es) Agonistas de guanilato ciclasa útiles en la preparación de medicamentos para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
WO2007101224A3 (en) Inhibitors of the unfolded protein response and methods for their use
JP2010222367A5 (es)
MY156275A (en) Compositions comprising tramadol and celecoxib in the treatment of pain
CL2012000333A1 (es) Antagonista del receptor de la endotelina útil en la prevención o el tratamiento de metástasis cerebral en combinación con un agente de quimioterapia citotóxico, radioterapia o ambos; su uso para inhibir protección mediada por astrocito de una célula cerebral metastasica de una muerte celular inducida por quimioterapia citotóxica; y su uso para tratar un tumor cerebral metastásico.
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
MX2010004613A (es) Composicion topica.
MX385881B (es) Forma de dosificacion de alivio prolongado
WO2015168488A3 (en) Islet amyloid polypeptides with improved solubility
EP2167071A4 (en) BACLOFEN SOLUTION FOR LOW VOLUME THERAPEUTIC DELIVERY
EP2371368A3 (en) Compositions and methods for treatment of inflammation and hyperkeratotic lesions
ZA201404068B (en) The use of silver(i) complexes as active pharmaceutical ingredients (api's) iincluding anticancer agents
EP2525819A4 (en) IMMUNOTHERAPY COMPOSITIONS AND TREATMENT PROCEDURES

Legal Events

Date Code Title Description
FG Grant or registration